Syntara Ltd
ASX:SNT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nabtesco Corp
TSE:6268
|
JP |
|
Lupin Ltd
NSE:LUPIN
|
IN |
|
Narumiya International Co Ltd
TSE:9275
|
JP |
|
S
|
Shopify Inc
F:307
|
CA |
|
Asia Potash International Investment Guangzhou Co Ltd
SZSE:000893
|
CN |
|
L
|
LapWall Oyj
OMXH:LAPWALL
|
FI |
|
S
|
Seco/Warwick SA
WSE:SWG
|
PL |
|
Farmer Bros Co
NASDAQ:FARM
|
US |
|
S
|
Stefanutti Stocks Holdings Ltd
JSE:SSK
|
ZA |
|
M
|
Multi Ways Holdings Ltd
AMEX:MWG
|
SG |
|
MJ Hudson Group PLC
LSE:MJH
|
JE |
|
Gusbourne PLC
LSE:GUS
|
UK |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| AU |
|
Syntara Ltd
ASX:SNT
|
50.6m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
235.8B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD |
Loading...
|
Market Distribution
| Min | -14 949 200% |
| 30th Percentile | -526.4% |
| Median | -25.2% |
| 70th Percentile | 6.1% |
| Max | 145 596.9% |
Other Profitability Ratios
Syntara Ltd
Glance View
Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Syntara Ltd is -175.6%, which is above its 3-year median of -188.6%.
Over the last 3 years, Syntara Ltd’s Operating Margin has decreased from -89.1% to -175.6%. During this period, it reached a low of -259.1% on Jun 30, 2024 and a high of -89.1% on Dec 31, 2022.
